"He went through six operations and was placed on a clinical trial so he could try new treatments.”
A trial looking at imatinib for glioma brain tumours (EORTC 16011-26013)
This trial looked at imatinib (Glivec) for people with a type of brain tumour called glioma that had come back after treatment.
Doctors usually treat gliomas with radiotherapy, surgery and sometimes chemotherapy. But sometimes gliomas can come back after treatment.
Doctors in this trial wanted to see how well imatinib worked for people with glioma that had come back. Imatinib is a type of biological therapy called a tyrosine kinase inhibitor.
The aims of this trial were to find out
- How well imatinib works for people with glioma
- More about the side effects
Summary of results
The researchers in this trial found that imatinib did not help people with glioma brain tumours that had come back.
The trial recruited 112 people who had different types of glioma’s including astrocytomas, ogligodendrogliomas and glioblastoma multiforme (GBM).
Everybody who took part had imatinib. Some people had a higher dose of imatinib than others. This depended on how the treatment was working. On average, people had 2 cycles of treatment.
The trial team analysed the results in 2008. They found
- In 5 people the cancer slowed or stopped growing – doctors call this a
- In 27 people the cancer stayed the same – doctors call this
- The treatment did not work for anybody else who took part
The main side effects were mild and included fluid build up and a drop in blood cell counts. The side effects were a little bit worse for the people who had higher dose imatinib.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Martin van den Bent
European Organisation for Research and Treatment of Cancer (EORTC)